Actavis acquired Allergan, Inc. on November 17, 2014 for $66 billion.
Allergan, Inc., is an American multinational pharmaceutical company that focuses on developing and marketing medical devices, pharmaceuticals, and over-the-counter consumer products.
It is based in Irvine, California.
The company was founded in 1950 by Gavin S. Herbert – a pharmacist who created the first antihistamine eye drop in the US.
Allergan now has a team of 10,500 employees and a presence in more than 100 countries. It operates manufacturing plants in Waco, Texas; San Jose, Costa Rica; Westport, Ireland; and Bridgewater, New Jersey.
Its leading products include: Botox® (onabotulinumtoxinA) for the treatment of overactive bladder with symptoms of urinary incontinence, Restasis® (cyclosporine ophthalmic emulsion) for chronic dry eye due to inﬂammation, Lumigan® (bimatoprost ophthalmic solution), Botox® Cosmetic (onabotulinumtoxinA) aesthetic medical treatment, and Juvéderm® dermal fillers.
In 2014, Valeant Pharmaceuticals International Inc. teamed up with Pershing Square Capital Management to make a hostile bid for the Botox maker.
- Chairman and CEO: David E.I. Pyott
- President: Douglas S. Ingram
- Industry: Pharmaceutical
- Type: Public company
- Formed: 1948
- Revenue: $7.237 billion USD (2014)
- Net earnings: $1,528.8 million USD (2014)
- Earnings per share: $5.12 USD (2014)
- Company head office: 2525 Dupont Drive, Irvine, CA 92612-1599, USA
- Employees: 10,500 (2014)
- Website: http://www.allergan.com/
- Investor relations number: (714) 246-4636
- Investor relations email: [email protected]
Allergan, Inc., Financial Results, Years Ended December 31
|Operating data (in $ millions)||2014||2013|
|Product net sales||$7,126.1||$6,197.5|
|Cost of sales||$842.4||$795.8|
|Selling, general and administrative costs||$2,837.2||$2,519.4|
|Research and development||$1,191.6||$1,042.3|
|Earnings from continuing operations||$1,532.6||$1,272.5|
|Net earnings attributable to Allergan, Inc.||$1,524.2||$985.1|
|Balance sheet data (in $ millions)|
|Total stockholders’ equity||$7,753.0||$6,463.2|
|Common share data (in $)|
|Basic earnings per share||$5.12||$3.32|
|Diluted earnings per share||$5.01||$3.26|
|Cash flow data (in $ millions)|
|Net cash provided by operating activities||$1,927.8||$1,695.4|
|Net cash used for investing activities||$182.7||$(1,375.3)|
|Net cash provided by (used for) financing activities||$(204.0)||$28.2|
|Cash and cash equivalents at beginning of year||$3,046.1||$2,701.8|
|Cash and cash equivalents at end of year||$4,911.4||$3,046.1|
Source: “Allergan, Inc. Form 10-K 2014”